ArticleBMC nephrology2025
Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study.Frontiers in immunology · 2026Observational
- Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to evaluate the efficacy and safety of low- to medium-dose (160 mg/W or 80 mg/W) telitacicept in adults at high risk of progression IgA nephropathy.
methodsThis was a single-center retrospective study. The study included adults with high risk progression of IgA nephropathy who were treated with telitacicept between November 2022 and April 2024 and followed for at least 24 weeks.
resultsIn this study of 11 patients, telitacicept significantly reduced proteinuria by 64.38% (p < 0.001) and increased eGFR by 23.18% (p = 0.005) at week 24. Both the 80 mg and 160 mg dose groups demonstrated significant reductions in proteinuria (68.67% and 59.23%, respectively, both p < 0.001) and urinary RBC counts. The overall response rate was 90.91%. Telitacicept demonstrated a favorable safety profile, with only mild injection-site reactions reported (18.2%) and no serious adverse events.
conclusionIn this real-world study, low- to medium-dose of telitacicept combined with conventional therapy showed rapid onset efficacy and safety for treating high-risk progressive IgA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.